Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of idelalisib in participants with relapsed
of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall
response rate.
Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg
twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable
toxicity.